MEDY-TOX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130,200 KRW | -1.74% |
|
-3.34% | -45.98% |
| Mar. 21 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 05 | South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing | MT |
| Sales 2024 * | 252B 183M | Sales 2025 * | 316B 229M | Capitalization | 876B 636M |
|---|---|---|---|---|---|
| Net income 2024 * | 43B 31.22M | Net income 2025 * | 70B 50.82M | EV / Sales 2024 * | 3.71 x |
| Net Debt 2024 * | 58.2B 42.25M | Net Debt 2025 * | 28.5B 20.69M | EV / Sales 2025 * | 2.87 x |
| P/E ratio 2024 * |
20.5
x | P/E ratio 2025 * |
13
x | Employees | 728 |
| Yield 2024 * |
0.85% | Yield 2025 * |
0.93% | Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.74% | ||
| 1 week | -3.34% | ||
| Current month | -10.52% | ||
| 1 month | -8.31% | ||
| 3 months | -39.58% | ||
| 6 months | -38.87% | ||
| Current year | -45.98% |
1 week
126 800.00
138 600.00
1 month
126 800.00150 400.00
Current year
126 800.00247 500.00
1 year
126 800.00316 500.00
3 years
94 952.38316 500.00
5 years
87 333.98525 095.85
10 years
87 333.98700 091.97
| Managers | Title | Age | Since |
|---|---|---|---|
Hyun-Ho Jeong
CEO | Chief Executive Officer | 61 | 00-05-01 |
Gi-Hyuk Yang
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Hee-Seok Joo
BRD | Director/Board Member | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyun-Ho Jeong
CEO | Chief Executive Officer | 61 | 00-05-01 |
Gi-Hyuk Yang
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Hee-Seok Joo
BRD | Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 2 M€ | -14.14% | ||
| 0.18% | 2 M€ | -.--% | ||
| 0.06% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 130,200 | -1.74% | 24 767 |
| 24-04-18 | 132,500 | +3.43% | 29,203 |
| 24-04-17 | 128,100 | -3.17% | 49,053 |
| 24-04-16 | 132,300 | -3.78% | 47,380 |
| 24-04-15 | 137,500 | +0.22% | 32,906 |
End-of-day quote Korea S.E., April 18, 2024
More quotes
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
130,200
KRW
Average target price
296,000
KRW
Spread / Average Target
+127.34%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.98% | 648M | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -25.59% | 27.69B | |
| +53.61% | 24.28B | |
| -7.72% | 17.09B | |
| -33.74% | 13.67B | |
| -16.74% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
- Stock Market
- Equities
- A086900 Stock
